Menveo

Menveo Caution For Usage

vaccine, meningococcal

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Full Prescribing Info
Caution For Usage
Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned in Special precautions for disposal and other handling as follows.
Special precautions for disposal and other handling:
The contents of the two components in the two different containers (MenA powder and MenCWY solution) are to be mixed prior to vaccination providing 1 dose of 0.5 ml.
Vial-Syringe presentation: Menveo must be prepared for administration by reconstituting powder (in vial) with solution (in pre-filled syringe).
The components of the vaccine should be visually inspected before and after reconstitution.
Remove the tip cap from the syringe and attach a suitable needle for the withdrawal (21G, 1 ½ inch length or a 21G, 40 mm length). Use the whole contents of the syringe (0.6 ml) to reconstitute the powder.
Invert and shake the vial vigorously and then withdraw 0.5 ml of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose.
Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine.
Prior to injection, change the needle for one suitable for the administration. Ensure that no air bubbles are present in the syringe before injecting the vaccine.
Vial-Vial presentation: Menveo must be prepared for administration by reconstituting powder (in vial) with solution (in vial).
The components of the vaccine should be visually inspected before and after reconstitution.
Using a syringe and a suitable needle (21G, 1 ½ inch length or a 21G, 40 mm length) withdraw the entire contents of the vial of solution and inject into the vial of powder to reconstitute the MenA conjugate component.
Invert and shake the vial vigorously and then withdraw 0.5 ml of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose.
Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine.
Prior to injection, change the needle for one suitable for the administration. Ensure that no air bubbles are present in the syringe before injecting the vaccine.
For all presentations: Previously frozen product should not be used. For a description on use, see Shelf life under Storage.
Special Precautions for disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in